GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkmate Pharmaceuticals Inc (NAS:CMPI) » Definitions » 3-Year FCF Growth Rate

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) 3-Year FCF Growth Rate : -0.50% (As of Mar. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Checkmate Pharmaceuticals 3-Year FCF Growth Rate?

Checkmate Pharmaceuticals's Free Cash Flow per Share for the three months ended in Mar. 2022 was $-0.49.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 4 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Checkmate Pharmaceuticals was -0.50% per year. The lowest was -0.50% per year. And the median was -0.50% per year.


Competitive Comparison of Checkmate Pharmaceuticals's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Checkmate Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkmate Pharmaceuticals's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkmate Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Checkmate Pharmaceuticals's 3-Year FCF Growth Rate falls into.



Checkmate Pharmaceuticals 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Checkmate Pharmaceuticals  (NAS:CMPI) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Checkmate Pharmaceuticals 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.
Executives
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Alan Bash director, officer: Chief Executive Officer C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jon Marc Wigginton director 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Joy Yan director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Arthur M Krieg director, officer: Chief Scientific Officer C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Robert Dolski officer: Chief Financial Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Barry Labinger director, officer: President and CEO C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Peter Colabuono director C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025
Oren Isacoff director C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Karen Brennan officer: Chief Operating Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Kleem Chaudhary officer: Chief Business Officer C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142
Venbio Global Strategic Gp Ii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Ii, Ltd. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Nilesh Kumar director C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6

Checkmate Pharmaceuticals (Checkmate Pharmaceuticals) Headlines

From GuruFocus

Novo Holdings A/S Buys 4, Sells 1 in 1st Quarter

By GuruFocus Research GuruFocus Editor 05-18-2022